Global Benign Prostatic Hyperplasia Treatment Market Size By Type (Drug Class, Minimally Invasive Surgeries), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts,...

The Global Benign Prostatic Hyperplasia (BPH) Treatment Market was valued at USD 11.4 billion in 2023 and is projected to surpass USD 18.2 billion by 2031, growing at a CAGR of 6.1% during the forecast period (2023–2031). This growth is driven by the rising prevalence of BPH among the aging male population, increasing awareness about prostate health, and the availability of minimally invasive treatment options. With a growing emphasis on quality of life and personalized healthcare, the BPH treatment market is witnessing strong demand across both developed and emerging economies.

Drivers:

1. Growing Geriatric Population:

BPH is strongly associated with aging, and the global increase in the elderly male demographic is a major factor propelling the market. Men over 50 are particularly vulnerable to this condition, driving a sustained demand for diagnosis and treatment.

2. Advancements in Minimally Invasive Therapies:

Technological innovations such as UroLift, Rezūm therapy, and laser-based interventions are gaining traction. These options offer improved patient outcomes, reduced hospital stays, and faster recovery, encouraging higher treatment uptake.

3. Increased Awareness and Screening Programs:

Rising health literacy and national screening initiatives are improving early diagnosis rates for BPH, translating to better disease management and fueling the growth of the treatment market.

Restraints:

1. Side Effects Associated with Drug Therapies:

Medications used to treat BPH, such as alpha-blockers and 5-alpha-reductase inhibitors, often lead to side effects including dizziness, sexual dysfunction, and hypotension, which may deter patient compliance.

2. High Cost of Surgical and Minimally Invasive Procedures:

Despite their efficacy, advanced treatments may be cost-prohibitive for patients without adequate health insurance, particularly in developing countries.

Opportunity:

1. Expanding Healthcare Infrastructure in Emerging Markets:

Countries across Asia-Pacific and Latin America are making significant investments in healthcare systems, providing greater access to diagnostic and therapeutic services for BPH.

2. Increasing R&D Investments and Product Approvals:

Ongoing clinical trials and FDA approvals for novel BPH treatment devices and drugs are expanding the therapeutic arsenal, presenting opportunities for both established and emerging market players.

Market by System Type Insights:

The market is segmented into pharmacological therapies, minimally invasive surgical therapies (MISTs), and surgical procedures. In 2023, pharmacological therapies accounted for the largest share due to the ease of administration and early disease management. However, minimally invasive therapies are expected to witness the fastest growth, supported by patient preference for less-invasive options and better outcomes.

Market by End-use Insights:

In terms of end-use, hospitals held the dominant market share in 2023, benefiting from comprehensive care facilities and skilled urologists. Ambulatory surgical centers (ASCs) are projected to grow rapidly due to their cost-effective and outpatient-based treatment capabilities, making them increasingly popular for MISTs.

Market by Regional Insights:

North America led the market in 2023, driven by a high prevalence of BPH, robust healthcare systems, and adoption of advanced therapies. Meanwhile, Asia-Pacific is expected to record the highest CAGR during the forecast period. Factors such as rising healthcare expenditure, increasing awareness, and growing elderly populations in countries like China and India are boosting regional growth.

Competitive Scenario:

Key market players in the BPH treatment landscape include Boston Scientific Corporation, Teleflex Incorporated, AbbVie Inc., GlaxoSmithKline plc, Lumenis Ltd., Olympus Corporation, Merck & Co., Inc., Asahi Kasei Corporation, Astellas Pharma Inc., and Urologix, LLC. These companies are investing in R&D, acquiring novel technologies, and expanding their global reach through partnerships and strategic launches.

Scope of Work – Global Benign Prostatic Hyperplasia Treatment Market

Report Metric Details

Market Size (2023) USD 11.4 billion

Projected Market Size (2031) USD 18.2 billion

CAGR (2023–2031) 6.1%

Market Segments System Type, End-use, Region

Growth Drivers Aging Population, Minimally Invasive Treatments, Awareness Programs

Opportunities Emerging Markets, Product Approvals & R&D Investments

Key Market Developments:

April 2024: Boston Scientific received FDA clearance for an advanced version of the UroLift System, designed for enhanced efficacy in larger prostates.

December 2023: Teleflex launched a next-gen Rezūm device in Europe with improved thermal therapy precision and reduced recovery time.

August 2023: Astellas Pharma initiated a Phase III clinical trial for a novel oral BPH therapy targeting hormone modulation with fewer sexual side effects.

FAQs:

1. What is the current market size of the Global Benign Prostatic Hyperplasia Treatment Market?

The market was valued at USD 11.4 billion in 2023.

2. What is the major growth driver of the Global Benign Prostatic Hyperplasia Treatment Market?

The primary growth driver is the increasing geriatric population coupled with rising adoption of minimally invasive therapies.

3. Which is the largest region during the forecast period in the Global Benign Prostatic Hyperplasia Treatment Market?

North America is expected to remain the largest regional market through 2031.

4. Which segment accounted for the largest market share in Global Benign Prostatic Hyperplasia Treatment Market?

Pharmacological therapies held the largest share in 2023 due to widespread use in early disease management.

5. Who are the key market players in the Global Benign Prostatic Hyperplasia Treatment Market?

Leading companies include Boston Scientific, Teleflex, AbbVie, GlaxoSmithKline, Lumenis, Olympus, and Astellas Pharma.